Clinical Impact of (18)F-FDG PET/CT in the Diagnostic Workup of Pancreatic Ductal Adenocarcinoma: A Systematic Review.
Clinical Impact of (18)F-FDG PET/CT in the Diagnostic Workup of Pancreatic Ductal Adenocarcinoma: A Systematic Review.
复制标题
DOI：
10.3390/diagnostics10121042
复制
发表时间：
2020-12-03
期刊：
影响因子：
--
通讯作者：
Alongi P
中科院分区：
文献类型：
--
作者：
Arnone A;Laudicella R;Caobelli F;Guglielmo P;Spallino M;Abenavoli E;Martini AL;Filice R;Comis AD;Cuzzocrea M;Linguanti F;Evangelista L;Alongi P
本文对氟脱氧葡萄糖(FDG)-正电子发射断层扫描(PET)/计算机断层扫描(CT)在胰腺导管腺癌(PDAC)诊断中的应用进行了评价。对截至2020年9月的文献进行全面检索，选择样本量为≥的10例患者和指数检验(即“FDG”或“18F-FDG”和“胰腺癌”或“胰腺癌”和“正电子发射断层扫描”)的研究。方法质量使用修订的诊断准确性研究质量评估(QUADAS-2)工具进行评估，并根据系统评价和荟萃分析(PRISMA)指南的首选报告项目提供。检索基本数据(作者、发表年份、国家和研究设计)、患者特征(登记受试者的数量和年龄)、疾病阶段、治疗类型和分级。46篇文章符合所采用的研究标准。根据所考虑的临床情况对文章进行分类。也就是说，除了常规的解剖成像，如计算机断层扫描(CT)和磁共振成像(MRI)，FDGPET/CT分子成像是PDAC的重要工具，适用于所有疾病阶段。进一步的前瞻性研究将有必要通过测试其在PDAC临床治疗中的真正潜在改善来证实这种成像技术的成本效益。
In this review, the performance of fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) in the diagnostic workup of pancreatic ductal adenocarcinoma (PDAC) is evaluated. A comprehensive literature search up to September 2020 was performed, selecting studies with the presence of: sample size ≥10 patients and index test (i.e., “FDG” or “18F-FDG” AND “pancreatic adenocarcinoma” or “pancreas cancer” AND “PET” or “positron emission tomography”). The methodological quality was evaluated using the revised quality assessment of diagnostic accuracy studies (QUADAS-2) tool and presented according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. Basic data (authors, year of publication, country and study design), patients’ characteristics (number of enrolled subjects and age), disease phase, type of treatment and grading were retrieved. Forty-six articles met the adopted research criteria. The articles were divided according to the considered clinical context. Namely, besides conventional anatomical imaging, such as computed tomography (CT) and magnetic resonance imaging (MRI), molecular imaging with FDG PET/CT is an important tool in PDAC, for all disease stages. Further prospective studies will be necessary to confirm the cost-effectiveness of such imaging techniques by testing its real potential improvement in the clinical management of PDAC.
登录
查看更多内容
影响因子：
2.4
作者：
Choi HJ;Lee JW;Kang B;Song SY;Lee JD;Lee JH
通讯作者：
Lee JH
影响因子：
1.6
作者：
Im HJ;Oo S;Jung W;Jang JY;Kim SW;Cheon GJ;Kang KW;Chung JK;Kim EE;Lee DS
通讯作者：
Lee DS
影响因子：
3
作者：
Chung, Kwang Hyun;Park, Joo Kyung;Hwang, Jin-Hyeok
通讯作者：
Hwang, Jin-Hyeok
影响因子：
3.6
作者：
Ghaneh，Paula;Hanson，Robert;Neoptolemos，John P.
通讯作者：
Neoptolemos，John P.
影响因子：
45.3
作者：
Ferrone, Cristina R.;Finkelstein, Dianne M.;Warshaw, Andrew L.
通讯作者：
Warshaw, Andrew L.